Bristol-Myers Squibb and Gilead Sciences formed a joint venture to develop and market a single pill for treating HIV-positive patients, possibly replacing the current regimen requiring a cocktail of two to four drugs a day. The pill the companies hope to market would combine three popular medicines into one tablet, targeted to debut in late 2006. Until now, the two companies have competed in the AIDS drug market. Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, told reporters he hopes the joint venture is "the beginning of future collaborations."
Published in Brief: